Nebenwirkungen · Orencia
ORENCIA 50 mg solution for injection in pre-filled syringe ORENCIA 87.5 mg solution for injection in pre-filled syringe ORENCIA 125 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 37
HOS-116133 · Präparat HOS-094411
Adverse reactions in patients with chronic obstructive pulmonary disease (COPD) In study IV, there were 37 patients with COPD treated with intravenous abatacept and 17 treated with placebo. The COPD patients treated with abatacept developed adverse reactions more frequently than those treated with placebo (51.4% vs. 47.1%, respectively). Respiratory disorders occurred more frequently in abatacept-treated patients than in placebo-treated patients (10.8% vs. 5.9%, respectively); these included COPD exacerbation, and dyspnoea. A greater percentage of abatacept- than placebo-treated patients with COPD developed a serious adverse reaction (5.4% vs. 0%), including COPD exacerbation (1 of 37 patients [2.7%]) and bronchitis (1 of 37 patients [2.7%]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-11T12:30:00Z · SHA-256 3a066717b7ce440eedd2e9279ed1947b4aca39773e492b7d91bc463fd23c42fd · Passage 141fd93a027f50d5442709234dfd1cecc09638e3518438600729c3128a38b640 · Zeichen 9020–9772 im Abschnitt